AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotechnology company Capstan Therapeutics, Inc., in a bid to boost its ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type 1 diabetes, hepatitis ...

In the past dozen years, doctors have tried no fewer than 50 promising drugs and other treatments for multiple sclerosis. In no case has the promise been fulfilled. “MS” remains an inexorable ...

According to a 2022 study, the estimated total economic burden of multiple sclerosis in the U.S. was $85.4 billion in 2019, with a direct medical cost of $63.3 billion; indirect and nonmedical ...

After a single dose of equecabtagene autoleucel, three people with progressive MS saw benefits, including improved walking ...

An illustration of damaged nerve cells caused by multiple sclerosis. In this image, the nerve cells are blue, and immune system cells are orange. ... Let’s start with a little immunology 101.

EBV infection has long been associated with multiple sclerosis, but how the infection might contribute to multiple sclerosis has not been clear. More than 95% of people have been infected with this ...

New advanced imaging technology that detects specific molecules in the brain may find signs of MS lesions months earlier, a ...

Impact of Multiple Sclerosis. ... $20, the research is being federally funded with the help of the National Institutes of Health’s Center for Human Immunology, Inflammation, ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Multiple sclerosis (MS) ... “There is a strong immunologic connection between the gut microbiome and central nervous system immunology and inflammation, ...

DNA recovered from the bones of ancient Europeans is shedding light on the genetic origins of the debilitating disease multiple sclerosis.